Fulyzaq
Active Ingredient(s): CrofelemerFDA Approved: * December 31, 2012
Pharm Company: * SALIX PHARMS
Category: Gastrointestinal
* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".
Fulyzaq Overview
Crofelemer (USAN, trade name Mytesi) is a botanical drug[1] for the treatment of diarrhea associated with anti-HIV drugs such as nucleoside analog reverse transcriptase inhibitors and protease inhibitors. Other possible uses include diarrhea in children, acute infectious diarrhea, and diarrhea in patients with irritable bowel syndrome.[2] It is a purified oligomeric proanthocyanidin from "dragon's blood", the sap of the South American tree Croton lechleri.&...
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Crofelemer
Recent Fulyzaq Forums:
Be the first to start a discussion about this drug.Possible Dosages for this and Related Drugs:
Crofelemer
- Tablet, Delayed Release: 125mg
NDC Database Records for Fulyzaq: (2 results)
Sorted by National Drug Code- 65649-802 Fulyzaq 125 mg Enteric Coated Tablet by Salix Pharmaceuticals, Inc.
- 70564-802 Fulyzaq 125 mg Oral Tablet, Coated by Napo Pharmaceuticals, Inc.